Researchers see new generation therapeutics to propel precision medicine
Posted on October 1, 2024 Updated on September 29, 2024
Researchers see a greater need for new generation therapeutics to propel precision medicine. The development of innovative therapeutic approaches in healthcare encompass a variety of fields, including gene therapy, personalized medicine, immunotherapy, and advanced biologics.
The current research areas of interest in India include precision medicine which treatments based on individual genetic profiles to improve efficacy and reduce side effects. Even gene editing has led to technologies like CRISPR allowing for precise modifications to DNA, potentially curing genetic disorders. The importance of biologics has led to developing therapies derived from living organisms, including monoclonal antibodies and vaccines. There is considerable attention to digital health integration by leveraging AI (artificial intelligence) and data analytics to improve drug discovery and patient management.
Also creating collaborative ecosystems has led to partnerships between academia, industry, and regulatory bodies to accelerate innovation. All this has accelerated approaches to be patient-centric approaches by engaging them in the therapeutic development process to ensure treatments meet their needs.
At the recently concluded Global-Bio India 2024 session on Steering New Generation Therapeutics moderated by Dr. Ajith Kamath, external R&D head, ex-Pfizer highlighted the shift towards biologics, which now comprise 40% of drugs. He noted that with opportunities in synthetic DNA and partnerships, the pharmaceutical sector is evolving rapidly.
Dr Gaurav Narula, paediatric oncology and haematology, Tata Memorial Hospital, Mumbai brought to the fore India’s first home-grown gene therapy for cancer: CAR-T cell therapy launched on April 4, 2024. This therapy was developed by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre.
Murali Ramachandra, CEO, Aurigene Oncology, Aurigene Discovery Technologies provided insights on advanced cancer treatments like Kinase inhibitors, small molecule immuno-oncology & CAR-T therapy. He emphasized that the 3 pillars of innovation: talent, funding and regulatory frameworks were critical components for steering new generation therapeutics.
Highlighting the advanced therapeutic strategies for Duchenne muscular dystrophy (DMD), a severe inherited disease that causes progressive muscle weakness and degeneration, Dr Shridhar Narayanan, CEO, Foundation of Neglected Disease Research and chief scientific advisor, Peptris Technologies said “Our pepAI algorithm enables activity prediction, molecular properties, toxicity screening and drug repurposing to target DMD effectively.”
Presenting details on discovering new drugs or repurposing old approved drugs for Duchenne muscular dystrophy, Dr Narayanan said, “PEPR112, a repurposed candidate, showed target engagement and biomarker up-regulation in a cell based assay followed by its efficacy in zebra fish and mice model of DMD. Peptris Technologies based out of C-CAMP in Bengaluru is an AI/ML (machine learning) company working on developing new drugs and repurposing old drugs.”
The others who chipped in their views on steering new generation therapeutics were Sanatan Upmanyu, head of data sciences, executive director at InveniAI GmbH and Dr Nitin Damle, EVP and chief innovation officer, Sun Pharma Advanced Research Company.
Source : 1
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://auroushealthcare.wordpress.com/2024/10/01/researchers-see-new-generation-therapeutics-to-propel-precision-medicine/